Krystal Biotech's VYJUVEK sees strong growth with $1B+ 2025 sales forecast. Check out why I rate KRYS as a Strong Buy and my ...

Krystal Biotech, Inc. (KRYS) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in earnings ...

Fourth quarter revenues increased 116% to $91.1 million versus fourth quarter of 2023Full year revenues increased 473% to $290.5 million versus ...

Shares of Krystal Biotech, Inc. (NASDAQ:KRYS – Get Free Report) have been given an average recommendation of “Buy” by the ...

South Side-based biotechnology firm Krystal Biotech Inc.'s stock is up 20% following its earnings call this morning.

The 12-month price targets, analyzed by analysts, offer insights with an average target of $217.33, a high estimate of $221.00, and a low estimate of $212.00. Surpassing the previous average price ...

Citi analyst Yigal Nochomovitz raised the firm’s price target on Krystal Biotech (KRYS) to $215 from $206 and keeps a Neutral rating on the ...

Shares of Krystal Biotech, Inc. (NASDAQ:KRYS – Get Free Report) rose 7.1% during mid-day trading on Thursday after Citigroup raised their price target on the stock from $206.00 to $215.00. Citigroup ...

Krystal Biotech Inc (NASDAQ:KRYS) is set to release its Q4 2024 earnings on Feb 19, 2025. The consensus estimate for Q4 2024 ...

Krystal Biotech KRYS reported fourth-quarter earnings per share of $1.52, which beat the Zacks Consensus Estimate of $1.29 as Vyjuvek gains traction in the U.S. market. In the year-ago quarter ...

Thank you for standing by and welcome to the Krystal Biotech Q4 2024 earnings call. (Operator Instructions) As a reminder, today's conference is being recorded. I would now like to hand the conference ...